Our 2018 Researcher Grants

Our 2018 Researcher Grants

Cure Cancer Australia announces it’s 2018 grant recipients funding 19 of Australia’s brightest early career researchers

 Philip Corne – Cure Cancer Australia Chairman, Dr Nick Gottardo – Cure Cancer Australia grant recipient

Philip Corne – Cure Cancer Australia Chairman, Dr Nick Gottardo – Cure Cancer Australia grant recipient

Cure Cancer Australia is delighted to announce support for 19 research grants in 2018. 

Today formally announced the names of the 11 early-career cancer researchers who have received new grants in 2018 to support their innovative work across many fields of cancer research. They join 8 researchers who are being funded this year in their second year of Cure Cancer Australia two-year grants.

“Cure Cancer Australia exclusively funds early-career researchers who offer new perspectives and innovative ideas across all areas of cancer research, because we believe that by supporting them, we have the best chance of one day finding a cure. Cure Cancer Australia is not only investing in research, but they’re investing in our future leaders in this field,” said Floyd Larsen, CEO Cure Cancer Australia.

Our Chairman, Philip Corne was delighted to attend the proceedings today at Peter McCallum Cancer Centre as the Federal Minister for Health, the Hon Greg Hunt announced the successful emerging research leaders awarded grants for 2018.

 

The 11 new Cure Cancer Australia 2018 grant recipients are:

 

Dr Angelica Merlot, University of Sydney, NSW

The spread of pancreatic cancer

Exploiting the ER Stress Pathways Against Pancreatic Cancer Metastasis

One year

Co funded by Cure Cancer Australia and Cancer Australia

Supported by The Can Too Foundation

 

Dr Kyohei Nakamura, QIMR Berghofer Medical Research Institute, QLD

Links between inflammation and multiple myeloma

Targeting the inflammatory microenvironment in multiple myeloma

One year

Co funded by Cure Cancer Australia and Cancer Australia

 

Dr Nicholas Fletcher, University of Queensland, QLD

New therapies for triple negative breast cancer

Aptamer targeted therapies for triple-negative breast cancer

One year

Solely supported by The Can Too Foundation

 

Dr Lauren Aoude, University of Queensland, QLD

Characteristics of melanoma

Genomics and biological correlates of radiomics in melanoma

One year

Solely supported by The Can Too Foundation

 

Dr Prahlad Raninga, QIMR Berghofer Medical Research Institute, QLD

New treatments for triple negative breast cancer

Targeting thioredoxin reductase 1 in novel combination therapies to treat triple negative breast cancer.

One year

Solely supported by The Can Too Foundation

 

Dr Najoua Lalaoui, The Walter and Eliza Hall Institute of Medical Research, VIC

New treatments for leukaemia

Targeting MK2 and IAP to treat leukemia.

Two years

Co funded by Cure Cancer Australia and Cancer Australia

 

Dr Orazio Vittorio, The Children's Cancer Institute Australia, NSW

Children’s cancer - new treatments for neuroblastoma

Targeting copper homeostasis as therapeutic strategy for neuroblastoma

Two years

Co funded by Cure Cancer Australia and Cancer Australia

Supported by Sydney Airport

 

Dr Donia Moujalled, Monash University, Australian Centre for Blood Diseases, VIC

New treatments for Acute Lymphoblastic Leukaemia

Targeting pro-survival programs in Acute Lymphoblastic Leukaemia (ALL)

Two years

Co funded by Cure Cancer Australia and Cancer Australia

 

Dr Kelly Brooks, QIMR Berghofer Medical Research Institute

Understanding changes leading to melanoma of the eye

Investigating changes in cancer cells caused by mutations in the gene PLCB4 in uveal (eye) melanoma and how these alterations can be used to develop new treatments

Two years

Co funded by Cure Cancer Australia and Cancer Australia

 

Dr Camille Guillerey, QIMR Berghofer Medical Research Institute

Developing preventative mechanisms for multiple myeloma

Blocking the inhibitory receptor TIGIT to restore immunity against multiple myeloma

Two years

Solely supported by The Can Too Foundation

 

Dr Mark Pinese, The Garvan Institute of Medical Research

Bioinformatics – identifying risk factors for sarcoma

Comprehensively surveying the complex genetic determinants of sarcoma risk

One Year

Supported by the Cure Cancer Australia Community

 

And the Cure Cancer Australia continuing grant recipients are;

 

Dr Lisa Mielke, Walter and Eliza Hall Institute of Medical Research, VIC

The role of protein IL-17 in gastrointestinal cancers

Transcriptional control of IL-17 producing T cells in gastrointestinal cancers.

Two Years

Co funded by Cure Cancer Australia and Cancer Australia

 

Dr Steven Lane, QIMR Berghofer Medical Research Institute, QLD

Understanding disease progression in blood cancers

Dnmt3a loss contributes to disease progression in myeloproliferative neoplasm

Two years

Co funded by Cure Cancer Australia and Cancer Australia

 

Dr Su Yin Lim, Macquarie University, NSW

Immunotherapy for melanoma

Differential effects of MAPK inhibition on immune activity determine melanoma response

Two years

Solely supported by The Can Too Foundation

 

Dr Jyotsna Batra, Queensland University of Technology, QLD

Biomarkers for prostate cancer

Functional and mechanistic characterisation of a novel LncRNA at chromosomal locus 5p15 in prostate cancer

Two years

Supported by the Cure Cancer Australia Community

 

Dr Fernando de Souza Fonseca Guimaraes, Walter and Eliza Hall Institute of Medical Research, VIC

Immunotherapy for melanoma

Targeting suppressive TGF-beta to enhance innate lymphoid cell response against melanoma

Two years

Solely supported by The Can Too Foundation

 

Dr Sumit Sahni, University of Sydney, NSW

Therapies for pancreatic cancer

Molecular Role of the AMPK-Dependent Pathway in the Activity of Thiosemicarbazones Against Pancreatic Cancer

Two years

Solely supported by The Can Too Foundation

 

Dr Yuan Cao, University of Melbourne, VIC

Immunotherapy for breast cancer treatment

Targeting matrix metalloproteinase-12 (MMP12) promotes an immune response against breast cancer

Two years

Solely supported by The Can Too Foundation

 

Dr George Sharbeen, Lowy Cancer Research Centre University of NSW, NSW

Developing treatments for pancreatic cancer

MutY-Homolog is a Potential Therapeutic Target for Pancreatic Cancer

Two years

Solely supported by The Can Too Foundation

 

There are also two additional grants, delayed from previous years;

 

Dr Gillian Gould, University of Newcastle, NSW

Smoking prevention for Aboriginal women

Assessing Behaviour Change Techniques for Indigenous Pregnant Smokers attending Aboriginal Medical Services - a nested study in a cluster Randomised Controlled Trial

One year (delayed from 2017)

Supported by The Can Too Foundation

Co funded by Cure Cancer Australia and Cancer Australia 

 

Dr Kate Van Dyke, University of Adelaide, SA

Mechanisms governing dissemination and relapse in multiple myeloma

Mechanisms governing dissemination and relapse in multiple myeloma: the role of hypoxia and the CCR1/CXCR4 axis

Two years (delayed from 2016)

 

For more information or to arrange an interview contact:

Lisa Shipman, Chief Marketing Officer
Cure Cancer Australia

Phone: (02) 8072 6188

... ...
Loading...